Proteolysis and deficiency of α1-proteinase inhibitor in SARS-CoV-2 infection
-
Published:2022
Issue:3
Volume:68
Page:157-176
-
ISSN:2310-6905
-
Container-title:Biomeditsinskaya Khimiya
-
language:ru
-
Short-container-title:BIOMED KHIM
Author:
Akbasheva O.E1, Spirina L.V.2, Dyakov D.A.1, Masunova N.V.1
Affiliation:
1. Siberian State Medical University, Tomsk, Russia 2. Siberian State Medical University, Tomsk, Russia; Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, Russia
Abstract
The SARS-CoV-2 pandemia had stimulated the numerous publications emergence on the α1-proteinase inhibitor (α1-PI, α1-antitrypsin), primarily when it was found that high mortality in some regions corresponded to the regions with deficient α1-PI alleles. By analogy with the last century's data, when the root cause of the α1-antitrypsin, genetic deficiency leading to the elastase activation in pulmonary emphysema, was proven. It is evident that proteolysis hyperactivation in COVID-19 may be associated with α1-PI impaired functions. The purpose of this review is to systematize scientific data, critical directions for translational studies on the role of α1-PI in SARS-CoV-2-induced proteolysis hyperactivation as a diagnostic marker and a target in therapy. This review describes the proteinase-dependent stages of a viral infection: the reception and virus penetration into the cell, the plasma aldosterone-angiotensin-renin, kinins, blood clotting systems imbalance. The ACE2, TMPRSS, ADAM17, furin, cathepsins, trypsin- and elastase-like serine proteinases role in the virus tropism, proteolytic cascades activation in blood, and the COVID-19-dependent complications is presented. The analysis of scientific reports on the α1-PI implementation in the SARS-CoV-2-induced inflammation, the links with the infection severity, and comorbidities were carried out. Particular attention is paid to the acquired α1-PI deficiency in assessing the patients with the proteolysis overactivation and chronic non-inflammatory diseases that are accompanied by the risk factors for the comorbidities progression, and the long-term consequences of COVID-19 initiation. Analyzed data on the search and proteases inhibitory drugs usage in the bronchopulmonary cardiovascular pathologies therapy are essential. It becomes evident the antiviral, anti-inflammatory, anticoagulant, anti-apoptotic effect of α1-PI. The prominent data and prospects for its application as a targeted drug in the SARS-CoV-2 acquired pneumonia and related disorders are presented.
Publisher
Institute of Biochemistry
Subject
General Biochemistry, Genetics and Molecular Biology,General Medicine
Reference207 articles.
1. Ghahramani S., Tabrizi R., Lankarani K.B., Kashani S.M., Rezaei S., Zeidi N., Akbari M., Heydari S.T., Akbari H., Nowrouzi-Sohrabi P., Ahmadizar F. (2020) Laboratory features of severe vs. non-severe COVID-19 patients in Asian populations: a systematic review and meta-analysis. Eur. J. Med. Res., 25(1), 30. 2. Wang F., Hou H., Wang T., Luo Y., Tang G., Wu S., Zhou H., Sun Z. (2020) Establishing a model for predicting the outcome of COVID-19 based on combination of laboratory tests. Travel. Med. Infect. Dis., 36, 101782. 3. Abdelrahman Z., Li M., Wang X. (2020) Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV and influenza A respiratory viruses. Front. Immunol., 11, 552909. 4. Azer S.A. (2020) COVID-19: pathophysiology, diagnosis, complications and investigational therapeutics. New Microbes New Infect., 37, 100738. 5. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y., Xia J., Yu T., Zhang X., Zhang L. (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 395(10223), 507-513.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|